ROD1 Antibody

What is ROD1 and what are its primary cellular functions?

ROD1 (regulator of differentiation 1), also known as PTBP3, is an RNA-binding protein that primarily mediates pre-mRNA alternative splicing regulation. It plays critical roles in the regulation of cell proliferation, differentiation, and migration. The protein contains multiple RNA-binding domains (RBDs), with RBD4 being particularly important for protein-protein interactions. ROD1 exists in multiple isoforms and can undergo post-translational modifications, resulting in molecular weights ranging from 55-59 kDa, although its calculated molecular weight is 60 kDa . Recent research has revealed ROD1's crucial involvement in immunological processes, particularly its role in defining AID (Activation-Induced Cytidine Deaminase)-binding sites genome-wide in activated B cells, which is essential for both class switch recombination (CSR) and somatic hypermutation (SHM) .

What are the key specifications of commonly used ROD1 antibodies?

Commercial ROD1 antibodies like the 14027-1-AP (rabbit polyclonal) target ROD1 across multiple species including human, mouse, and rat samples. The antibody is typically generated using ROD1 fusion protein immunogens and purified via antigen affinity methods. These antibodies recognize the protein that has a calculated molecular weight of 60 kDa but is typically observed at 55-59 kDa in experimental conditions. The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, and the recommended storage temperature is -20°C, where it remains stable for approximately one year after shipment .

What is the difference between ROD1 (PTBP3) and ROBO1?

This is a critical distinction that researchers must understand. ROD1 (PTBP3) is an RNA-binding protein involved in pre-mRNA splicing and regulation of various cellular processes. In contrast, ROBO1 is a membrane protein that contributes to tumor metastasis and angiogenesis, often studied in the context of cancer models such as small cell lung cancer (SCLC) . Despite the similar nomenclature, these proteins have different structures, cellular localizations, and functions. ROD1 antibodies will not cross-react with ROBO1 proteins, and vice versa, making proper antibody selection crucial for experimental accuracy.

What are the validated applications for ROD1 antibodies and their recommended dilutions?

ROD1 antibodies have been validated for multiple experimental applications:

Researchers should note that optimal dilutions may be sample-dependent, and it is recommended to titrate the antibody in each specific testing system to obtain optimal results . For immunohistochemistry applications specifically, antigen retrieval with TE buffer pH 9.0 is suggested, though citrate buffer pH 6.0 may be used as an alternative .

How should I design ROD1 knockdown/knockout experiments for functional studies?

When designing ROD1 knockdown or knockout experiments, consider targeting specific exons that are critical for protein function. As demonstrated in previous research, disrupting exon 3 or exon 5 with different gRNAs has successfully generated ROD1-deficient mice . When conducting these experiments, it's essential to confirm the ablation of ROD1 using Western blotting. Important considerations include verifying that ROD1 knockout does not affect the expression levels of interacting partners like AID. Additionally, phenotypic analysis should include examining the structure and function of organs where ROD1 is known to be expressed, such as spleen, lung, testis and thymus. For in vitro experiments, both siRNA and CRISPR-Cas9 approaches have been successfully employed, but careful validation of knockdown efficiency and specificity is crucial .

What controls should be included when using ROD1 antibodies in immunoprecipitation experiments?

For immunoprecipitation experiments using ROD1 antibodies, several critical controls must be included:

• Input control: A small portion of the pre-cleared lysate should be saved to confirm protein expression in the starting material.

• Negative antibody control: Use an isotype-matched control antibody (e.g., IgG from the same species) that doesn't recognize any relevant proteins in your system.

• DNase/RNase treatment controls: Since ROD1 is an RNA-binding protein, include controls with DNase I or RNase A treatment to determine if the interactions are dependent on nucleic acids. Previous research has shown that the interaction between ROD1 and proteins like AID remains stable even after nuclease treatment, indicating a direct protein-protein interaction .

• Reciprocal immunoprecipitation: When studying protein-protein interactions, perform immunoprecipitation with antibodies against both ROD1 and its potential interacting partners.

• Knockout/knockdown controls: Include samples from ROD1-deficient cells to confirm antibody specificity and eliminate false positives.

How can I optimize immunohistochemistry protocols for ROD1 detection in tissue samples?

Optimizing immunohistochemistry for ROD1 detection requires careful attention to several parameters:

• Fixation and embedding: Tissue samples should be fixed in 4% paraformaldehyde overnight at 4°C before paraffin embedding.

• Section thickness: Prepare sections of 3-5 μm thickness for optimal staining.

• Antigen retrieval: This is critical for ROD1 detection. Use 10 mM Tris-1 mM EDTA buffer (pH 9.0) in a pressure cooker for 20 minutes. Alternatively, citrate buffer (pH 6.0) may be used, though potentially with different results .

• Blocking: Quench endogenous peroxidase with 0.3% hydrogen peroxide-methanol for 30 minutes, followed by blocking with 5% normal goat serum for 1 hour.

• Primary antibody incubation: Use ROD1 antibody at a dilution of 1:20-1:200, incubating overnight at 4°C.

• Detection system: Apply an appropriate secondary antibody system (e.g., Simple stain MAX-PO) at room temperature for 30 minutes .

• Validation: Include positive control tissues known to express ROD1 (such as lymphoid tissues) and negative controls (primary antibody omitted) in each staining batch.

How does ROD1 interact with AID in B cells, and how can this interaction be studied?

ROD1 directly interacts with AID (Activation-Induced Cytidine Deaminase) in activated B cells, playing a crucial role in defining AID-binding sites genome-wide. This interaction occurs via an ultraconserved loop in the RBD4 domain of ROD1 that fits into a pocket structure in AID. To study this interaction:

• Co-immunoprecipitation (co-IP) can be used to demonstrate the endogenous interaction between ROD1 and AID in activated B cells, such as those stimulated with LPS. This interaction remains stable even after DNase I or RNase A treatment, indicating a direct protein-protein interaction independent of nucleic acids .

• In vitro pull-down assays with bacterially expressed His-ROD1 and GST-AID can confirm direct interaction. Structure-based analysis using truncation mutants has revealed that the C-terminus of ROD1 containing RBD4 directly binds AID .

• Mutation analysis targeting specific residues (H506, E510, and H512) within the conserved loop of ROD1 can demonstrate their critical role in AID binding. Similarly, loop-deleted forms of ROD1 fail to interact with AID .

• Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) can assess how ROD1 regulates AID targeting to specific genomic loci, particularly in the context of class switch recombination and somatic hypermutation .

What is the relationship between ROD1 and miR-210 under hypoxic conditions?

ROD1 has been identified as a seedless target gene of hypoxia-induced miR-210. Under hypoxic conditions, miR-210 expression increases, leading to downregulation of ROD1 at both mRNA and protein levels. This relationship can be studied through several experimental approaches:

• RNA-induced silencing complex (RISC) immunoprecipitation: By co-transfecting cells with miR-210 and c-myc-Ago2 (a component of RISC), followed by immunoprecipitation using c-myc antibody, researchers can demonstrate enrichment of ROD1 mRNA in miR-210-containing RISC complexes .

• miR-210 modulation studies: Overexpression of miR-210 leads to downregulation of ROD1 protein and mRNA. Conversely, inhibition of miR-210 using specific LNA-anti-miR-210 sequences in hypoxic conditions rescues ROD1 expression, confirming the miR-210-dependent regulation .

• Hypoxia experiments: Exposing cells to hypoxic conditions while modulating miR-210 levels (through overexpression or inhibition) can demonstrate the functional relationship between hypoxia, miR-210, and ROD1 expression .

• Quantitative analysis: Western blotting and qPCR should be used to quantify changes in ROD1 protein and mRNA levels, respectively, following miR-210 modulation or hypoxic conditions .

How can ChIP-seq be optimized for studying ROD1 binding to chromatin?

Optimizing ChIP-seq for ROD1 requires careful consideration of several technical aspects:

• Crosslinking conditions: Since ROD1 is an RNA-binding protein that interacts with both RNA and other proteins, dual crosslinking with both formaldehyde (1% for 10 minutes) and a protein-protein crosslinker like DSG (disuccinimidyl glutarate) may improve capture of ROD1-containing complexes.

• Antibody selection and validation: Choose a ChIP-grade ROD1 antibody and validate its specificity using ROD1-knockout cells as negative controls. Pre-clearing the chromatin with protein A/G beads before immunoprecipitation can reduce background.

• Sonication parameters: Optimize sonication conditions to generate DNA fragments of 200-500 bp, which is ideal for high-resolution mapping of binding sites. Verify fragmentation efficiency by agarose gel electrophoresis.

• Controls: Include input controls, IgG controls, and positive controls (regions known to be bound by ROD1 or its interacting partners). Also consider including ROD1-knockout cells as biological negative controls.

• Data analysis: Given ROD1's role in pre-mRNA processing, analyze binding patterns relative to transcriptional units, splicing sites, and regions of bidirectional transcription. Integration with RNA-seq and other epigenomic data can provide functional context.

• RIP-seq integration: Consider complementing ChIP-seq with RIP-seq (RNA Immunoprecipitation followed by sequencing) to identify RNA species that might mediate ROD1 interaction with chromatin.

Why might I observe multiple bands when performing Western blot for ROD1?

Multiple bands in ROD1 Western blots can occur for several reasons:

• Isoform variation: ROD1 exists in multiple isoforms, which can result in bands of different molecular weights. The observed molecular weight of ROD1 typically ranges from 55-59 kDa, while the calculated molecular weight is 60 kDa .

• Post-translational modifications: ROD1 undergoes various modifications that can alter its electrophoretic mobility. These modifications may be tissue or cell-type specific.

• Proteolytic degradation: Incomplete protease inhibition during sample preparation can lead to degradation products. Ensure fresh protease inhibitors are added to all buffers during sample preparation.

• Antibody specificity: Some antibodies may recognize epitopes present in multiple proteins. Validate specificity using ROD1 knockout or knockdown samples as negative controls.

• Non-specific binding: Optimize blocking conditions, antibody dilution, and washing steps to reduce background. Consider using 5% BSA instead of milk for blocking if background is high.

To address these issues, include positive controls like HL-60 cells, mouse thymus tissue, HeLa cells, Jurkat cells, or rat thymus tissue, which have been validated for ROD1 detection . Additionally, titrate antibody concentrations and consider using gradient gels to better resolve proteins with similar molecular weights.

How can I validate the specificity of ROD1 antibodies in my experimental system?

Validating ROD1 antibody specificity is crucial for reliable results:

• Genetic validation: The gold standard approach is using ROD1 knockout or knockdown models. Compare antibody reactivity in wild-type versus ROD1-deficient samples across all applications (Western blot, IHC, IP, etc.).

• Peptide competition assay: Pre-incubate the antibody with excess purified ROD1 protein or the immunizing peptide before application to your samples. Specific signals should be significantly reduced or eliminated.

• Multiple antibody validation: Use multiple antibodies targeting different epitopes of ROD1 and compare the results. Consistent patterns across different antibodies increase confidence in specificity.

• Signal correlation with expression level: Demonstrate that signal intensity correlates with known or experimentally induced variations in ROD1 expression levels across different cell types or conditions.

• Mass spectrometry: For immunoprecipitation applications, confirm the identity of the pulled-down protein using mass spectrometry.

• Cross-reactivity assessment: Test antibody reactivity in tissues or cells from different species to confirm the expected species reactivity profile matches the supplier's claims .

What are the potential pitfalls when studying ROD1-RNA interactions?

Studying ROD1-RNA interactions presents several challenges:

• RNA degradation: RNA is highly susceptible to degradation by ubiquitous RNases. Use RNase-free reagents, DEPC-treated water, and RNase inhibitors throughout sample preparation.

• Distinguishing direct vs. indirect interactions: ROD1 may interact with RNA directly or as part of larger ribonucleoprotein complexes. UV crosslinking prior to immunoprecipitation can help identify direct protein-RNA contacts.

• Non-specific RNA binding: RNA-binding proteins can show non-specific binding to RNA, especially in high-salt conditions. Include proper controls and optimize wash conditions to reduce background.

• Context-dependent interactions: ROD1-RNA interactions may be influenced by cellular context, post-translational modifications, or presence of cofactors. Consider studying these interactions under different physiological conditions, such as hypoxia, which affects ROD1 expression through miR-210 .

• Detection sensitivity: Some ROD1-RNA interactions may be transient or involve low-abundance RNAs. Consider using highly sensitive techniques like CLIP-seq (Crosslinking and Immunoprecipitation followed by sequencing) or PAR-CLIP to capture these interactions.

• Functional validation: Showing binding is insufficient; functional consequences of the interaction should be validated using methods like minigene splicing assays or RNA stability measurements after ROD1 modulation.

How might ROD1's role in AID targeting inform therapeutic approaches for antibody-related disorders?

ROD1's essential role in AID targeting has significant implications for disorders involving antibody dysregulation:

• Hyper-IgM syndrome type 2 (HIGM2): Research has shown that AID-specific mutations identified in HIGM2 patients disrupt the AID interacting surface with ROD1, abolishing the recruitment of AID to immunoglobulin loci . This insight could inform the development of small molecule modulators that either disrupt or enhance this interaction, depending on the therapeutic goal.

• Autoimmune disorders: Since ROD1 is crucial for both class switch recombination (CSR) and somatic hypermutation (SHM), it represents a potential target for modulating aberrant antibody production in autoimmune conditions. Developing compounds that selectively inhibit ROD1's interaction with AID might reduce pathogenic antibody diversity without broadly suppressing the immune system.

• Diagnostic applications: Characterizing the ROD1-AID interaction could lead to novel biomarkers for predicting antibody-related disorder progression or treatment response. Patients with variations in either ROD1 or AID might exhibit different disease trajectories or therapeutic responses.

• Gene therapy approaches: For patients with mutations affecting the ROD1-AID interaction, targeted gene therapy might restore normal antibody diversification processes. This could involve delivering modified ROD1 or AID variants that can interact despite mutations.

• B cell engineering: Understanding ROD1's role could enhance methods for engineering B cells with desired antibody characteristics for therapeutic antibody production or adoptive cell therapies.

What role might ROD1 play in cancer biology through its regulation by miR-210 under hypoxic conditions?

The regulation of ROD1 by miR-210 under hypoxic conditions suggests potential roles in cancer biology:

• Tumor microenvironment adaptation: Since solid tumors often contain hypoxic regions, the miR-210-mediated downregulation of ROD1 may contribute to cancer cell adaptation to low oxygen environments . This could influence tumor progression through alterations in RNA splicing patterns.

• Cancer cell migration and invasion: Given ROD1's role in cell migration, its downregulation by miR-210 under hypoxia might affect cancer cell motility and invasion potential, potentially contributing to metastatic processes.

• Therapeutic resistance: Hypoxia is associated with resistance to various cancer therapies. ROD1's regulation by miR-210 could be part of the mechanism by which cancer cells alter their gene expression programs to develop treatment resistance.

• Biomarker potential: The miR-210/ROD1 axis could serve as a prognostic or predictive biomarker in cancers characterized by hypoxic microenvironments. Measuring this relationship might help stratify patients for targeted therapies.

• Future therapeutic target: Manipulating the miR-210/ROD1 axis could represent a novel therapeutic approach in cancers where hypoxia plays a significant role. This could involve miR-210 inhibitors or direct targeting of ROD1 to normalize its expression in hypoxic tumor regions.